CB2 may act by modulating the levels of IL-6 under low inflammatory conditions, while CB2−/− females, which have increased IL-6 levels (Figure 2) even under non-inflammatory conditions, are at a higher risk for colon cancer in the steady-state because of the IL-6-induced upregulation of MDSCs. This evidence concerns the gene IL6 and malignant colon neoplasm.